EICHOR
● Active Not Recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Condition: Neovascular Age-related Macular Degeneration (nAMD) · Sponsor: Hoffmann-La Roche
About this study
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (104)
| Centro Oftalmologico Dr. Charles S.A. | Capital Federal, Argentina | — |
| Oftalmos | Capital Federal, Argentina | — |
| Grupo Laser Vision | Rosario, Argentina | — |
| Eyeclinic Albury Wodonga | Albury, New South Wales, Australia | — |
| Eye and Retina Consultants | Hurstville, New South Wales, Australia | — |
| Retina Associates Liverpool | Liverpool, New South Wales, Australia | — |
| Retina and Macula Specialists | Miranda, New South Wales, Australia | — |
| Sydney Eye Hospital | Sydney, New South Wales, Australia | — |
| Sydney Retina Clinic and Day Surgery | Sydney, New South Wales, Australia | — |
| Queensland Eye Institute | Woolloongabba, Queensland, Australia | — |
| Centre For Eye Research Australia | East Melbourne, Victoria, Australia | — |
| Retina Specialists Victoria | Rowville, Victoria, Australia | — |
+ 92 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04657289